Table 2.
Univariate analysis for OS (N = 122)
| Median OS, mo | HR | 95% CI | P | |
|---|---|---|---|---|
| MPN diagnosis at time of AP/BP | .59 | |||
| PV/PPV-MF | 4.3 | 1.00 | — | |
| ET/PET-MF | 6.5 | 0.72 | 0.44-1.17 | |
| PMF | 8.6 | 0.85 | 0.52-1.39 | |
| MPN-U | 7.4 | 0.98 | 0.48-1.98 | |
| Age at AP/BP, y* | 1.02 | 1.01-1.04 | .01 | |
| Year of AP/BP diagnosis | .45 | |||
| 1997-2007 | 9.7 | 1.00 | — | |
| 2008-2017 | 5.7 | 1.20 | 0.75-1.90 | |
| Prior MPN therapies | .38 | |||
| 0 or 1 | 8.6 | 1.00 | — | |
| 2 | 4.2 | 1.44 | 0.88-2.38 | |
| ≥3 | 4.0 | 1.10 | 0.66-1.82 | |
| ECOG at AP/BP | .002 | |||
| 0 or 1 | 8.8 | 1.00 | — | |
| 2 | 2.6 | 1.74 | 0.98-3.11 | |
| ≥3 | 1.7 | 3.25 | 1.74-6.09 | |
| Hemoglobin* | 0.99 | 0.98-1.00 | .13 | |
| White blood cells* | 1.00 | 1.00-1.01 | .36 | |
| Platelets* | 1.00 | 1.00-1.00 | .07 | |
| Blasts in PB* | 1.01 | 1.01-1.02 | .0003 | |
| Blasts in BM* | 1.01 | 1.00-1.02 | .01 | |
| LDH* | 1.00 | 1.00-1.00 | .22 | |
| Albumin* | 0.92 | 0.88-0.97 | .001 | |
| Spleen status | .13 | |||
| Splenectomy | 3.0 | 1.00 | — | |
| Not palpable | 8.6 | 0.41 | 0.19-0.91 | |
| Spleen ≤10 cm BCM | 5.1 | 0.66 | 0.30-1.45 | |
| Spleen ≥11 cm BCM | 8.8 | 0.47 | 0.21-1.04 | |
| Missing | 5.2 | 0.80 | 0.28-2.30 | |
| Cytogenetic abnormalities | .004 | |||
| Normal | 13.2 | 1.00 | ||
| 1 | 9.2 | 1.07 | 0.56-2.03 | |
| 2 | 5.2 | 1.53 | 0.76-3.08 | |
| ≥3 | 3.0 | 2.64 | 1.52-4.57 | |
| Treatment received | <.0001 | |||
| Intensive | 9.8 | 1.00 | — | |
| Nonintensive | 12.1 | 0.95 | 0.55-1.65 | |
| BSC | 2.0 | 2.97 | 1.90-4.64 | |
| Number of mutations | .02 | |||
| 0-1 | 9.4 | 1.00 | — | |
| 2-3 | 7.3 | 1.27 | 0.72-2.24 | |
| ≥4 | 3.4 | 2.04 | 1.15-3.65 | |
| JAK2 V617F (n = 67) | .36 | |||
| Yes | 4.4 | — | — | |
| No | 7.3 | 0.84 | 0.57-1.23 | |
| CALR (n = 16) | .21 | |||
| Yes | 11.4 | — | — | |
| No | 5.7 | 1.45 | 0.79-2.65 | |
| MPL (n = 7) | .47 | |||
| Yes | 3.4 | — | — | |
| No | 6.0 | 0.75 | 0.35-1.61 | |
| ASXL1 (n = 36) | .91 | |||
| Yes | 7.0 | — | — | |
| No | 5.8 | 0.98 | 0.64-1.50 | |
| DMNT3A (n = 20) | ||||
| Yes | 4.4 | — | — | .97 |
| No | 6.5 | 0.98 | 0.56-1.74 | |
| EZH2 (n = 9) | ||||
| Yes | 10.8 | — | — | .81 |
| No | 5.8 | 0.92 | 0.44-1.89 | |
| IDH1 (n = 16) | ||||
| Yes | 4.4 | — | — | .53 |
| No | 6.0 | 0.83 | 0.47-1.46 | |
| IDH2 (n = 16) | ||||
| Yes | 5.1 | — | — | .71 |
| No | 6.2 | 1.12 | 0.61-2.04 | |
| KRAS (n = 8) | ||||
| Yes | 1.2 | — | — | .10 |
| No | 6.9 | 0.49 | 0.23-1.06 | |
| NRAS (n = 13) | ||||
| Yes | 2.7 | — | — | .73 |
| No | 6.0 | 0.89 | 0.45-1.67 | |
| PHF6 (n = 8) | ||||
| Yes | 3.8 | — | — | .25 |
| No | 6.2 | 0.62 | 0.28-1.33 | |
| RUNX1 (n = 25) | ||||
| Yes | 5.2 | — | — | .17 |
| No | 6.5 | 0.71 | 0.44-1.15 | |
| SETBP1 (n = 11) | ||||
| Yes | 7.0 | — | — | .94 |
| No | 5.8 | 1.03 | 0.52-2.04 | |
| SF3B1 (n = 9) | ||||
| Yes | 6.9 | — | — | .84 |
| No | 5.8 | 0.93 | 0.45-1.91 | |
| SRSF2 (n = 27) | ||||
| Yes | 9.8 | — | — | .40 |
| No | 5.8 | 1.22 | 0.76-1.97 | |
| STAG2 (n = 14) | ||||
| Yes | 2.3 | — | — | .71 |
| No | 6.2 | 0.90 | 0.51-1.58 | |
| TET2 (n = 30) | ||||
| Yes | 3.9 | — | — | .10 |
| No | 7.0 | 0.68 | 0.44-1.06 | |
| TP53 (n = 21) | ||||
| Yes | 3.6 | — | — | .03 |
| No | 7.0 | 0.53 | 0.32-0.89 | |
| U2AF (n = 11) | ||||
| Yes | 4.2 | — | — | .24 |
| No | 6.5 | 0.67 | 0.36-1.26 |
CI, confidence interval.
*
Continuous variable.